Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CRIT peptide interacts with factor B and interferes with alternative pathway activation.

Kwok-Min Hui1, Bergljót Magnadóttir, Jürg A Schifferli

  • 1University Hospital Basel, Immunonephrology, Department of Research, Hebelstrasse 20, CH-4031 Basel, Switzerland. 12min@mail.hongkong.com

Biochemical and Biophysical Research Communications
|April 8, 2006
PubMed
Summary

Complement C2 receptor inhibitor trispanning (CRIT) peptide CRIT-H17 blocks alternative pathway (AP) complement activation by inhibiting factor B cleavage. This peptide shows potential for modulating AP-driven inflammatory diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In differentiated HL-60 neutrophil-like cells, MRP1- (ABCC1-) mediated glutathione efflux stimulated by BzATP and P2X<sub>7</sub> receptor signalling regulates exosome release through nSMase activity.

Biochemical and biophysical research communications·2026
Same author

Profiling Protein Citrullination in Extracellular Vesicles by Single-Molecule Detection Using Direct Stochastic Optical Reconstruction Microscopy.

Journal of biophotonics·2025
Same author

Extracellular Vesicles from the Myocyte Secretome Contribute In Vitro to Creating an Unfavourable Environment for Migrating Lung Carcinoma Cells.

Biology·2025
Same author

Exploring the Potential of Extracellular Vesicles from Atlantic Cod (<i>Gadus morhua</i> L.) Serum and Mucus for Wound Healing In Vitro.

Biology·2025
Same author

Urinary Extracellular Vesicle Signatures as Biomarkers in Prostate Cancer Patients.

International journal of molecular sciences·2025
Same author

Animal Models of Human Disease 2.0.

International journal of molecular sciences·2025

Area of Science:

  • Immunology
  • Complement system biology

Background:

  • Complement C2 receptor inhibitor trispanning (CRIT) targets the classical pathway (CP) C3 convertase.
  • The C-terminal peptide CRIT-H17 mimics C4b binding to C2.
  • Similarities exist between CP and alternative pathway (AP) C3 convertases.

Purpose of the Study:

  • To investigate the effect of CRIT-H17 on the AP of the complement system.
  • To determine the mechanism of CRIT-H17 inhibition on AP activation.

Main Methods:

  • ELISA and immunoblot assays to detect CRIT-H17 binding to factor B (FB).
  • Inhibition assays for factor D-mediated cleavage of FB.
  • Hemolytic assays using C2-deficient serum to assess AP activation.

Main Results:

Related Experiment Videos

  • CRIT-H17 blocked factor D-mediated cleavage of factor B.
  • CRIT-H17 directly bound to factor B.
  • CRIT-H17 did not affect C3bB complex assembly or exhibit decay-accelerating activity.
  • CRIT-H17 inhibited AP complement activation in a hemolytic assay.

Conclusions:

  • CRIT-H17 peptide inhibits AP complement activation by interfering with factor B function.
  • CRIT-H17 represents a potential therapeutic agent for AP-mediated diseases.